Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis
- Sponsor
- University Hospital, Rouen
- Study ID
- NCT01765374
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ESAOTE MyLab60 — DEVICEUS evaluation at different time points
- Rituximab — DRUG
Study Details
To detect by sonography relapse of disease activity prior to clinical symptoms in RA patients treated by rituximab.
Key Dates
- Start date
- Feb 28, 2011
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: rituximabOnly one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
Primary Outcome Measure
global score of power-doppler activity measured by ultrasonography on 12 joints [ Time Frame: at 6 months after initiation of rituximab and then every 2 month over the follow-up period (18 months) ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina